Loading market movers...

Talquetamab

Phase 3

Johnson & Johnson (JNJ)

00%

Phase 3

Development Phase

2

Upcoming Catalysts

0

Historical Events

1

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Aug '27

JNJPhase 2$649.6B

Talquetamab Phase 2 Est. Readout

Talquetamab• Multiple Myeloma100

Aug 2027~Confirmed

00%

Q3 '27

JNJPhase 3$649.6B

Talquetamab Phase 3 Est. Readout

Talquetamab• Multiple Myeloma864

Q3 2027~QConfirmedSTALE

00%

Competitive Landscape

18 competitors in Multiple Myeloma

ADPTMRD Testing

CHCTciltacabtagene autoleucel

DFPHCAR T Cell Therapy

View Full Landscape

Drug Information

Target Indication

Multiple Myeloma

Clinical Trial

Last updated: 5/28/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA8/21/2023

Talvey

Talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti CD38 antibody and have demonstrated disease progression on the last therapy.

OrphanConditionalPRIME

Drug Science

Mechanism of action & safety profile

Developer

JNJ

Johnson & Johnson

Pharmaceutical Preparations•North America•NYSE

Related Pipeline

galantamine ERPhase 3

Alzheimer's Disease

Test acetaminophenPhase 3

Post-operative Dental Pain

CG 5503;tapentadolPhase 3

Osteoarthritis

tapentadol (CG5503) ERPhase 3

Low Back Pain

levofloxacinPhase 3

Pneumonia

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts